DCTH · Delcath Systems, Inc. · Insider Trading
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-11-12 | Martell Bridget A |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.20 to $22.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
1,930 |
| 2026-11-12 | Martell Bridget A |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 23, 2024 and monthly thereafter for so long as the reporting person remains a director of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2026-11-12 | Martell Bridget A |
Director |
Convert↑
|
Common Stock
|
22,500 |
| 2026-11-12 | Martell Bridget A |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.20 to $22.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Common Stock
|
20,570 |
| 2026-10-13 | Rosalind Advisors, Inc. |
Director |
Other↑
Filing footnotes — Common Stock (Indirect)
Rosalind Opportunities Fund I L.P. converted 36.27 shares of Series E Preferred Stock to acquire 3,627 common shares. Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common Stock
(I)
|
3,627 |
| 2026-10-13 | Rosalind Advisors, Inc. |
Director |
Other↓
Filing footnotes — Series E preferred (Indirect)
Rosalind Opportunities Fund I L.P. converted 36.27 shares of Series E Preferred Stock to acquire 3,627 common shares. The Series E Preferred Stock has no expiration date and is immediately convertible. Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Series E preferred
(I)
|
36 |
| 2026-10-13 | Rosalind Advisors, Inc. |
Director |
Other↓
Filing footnotes — Common Stock (Indirect)
Shares distributed in kind by Rosalind Opportunities Fund I L.P. to limited partners in satisfaction of redemption requests, for no consideration. Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common Stock
(I)
|
27,502 |
| 2026-05-13 | CZEREPAK ELIZABETH |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2026-05-13 | Aharon Gil |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2026-05-13 | Martell Bridget A |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2026-05-13 | SALAMON STEVEN A J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2026-05-13 | Sylvester John Richard |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2026-03-06 | Pennell Sandra |
Chief Financial Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
Includes an aggregate of 10,433 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan. |
Common Stock
|
5,533 |
| 2026-03-02 | MICHEL GERARD J |
Director, CHIEF EXECUTIVE OFFICER |
Buy↑
|
Common Stock
|
11,200 |
| 2026-02-17 | Rook Martha S. |
CHIEF OPERATING OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
56,500 |
| 2026-02-17 | Vukovic Vojo |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Restricted Stock Units
|
28,250 |
| 2026-02-17 | Pennell Sandra |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
56,500 |
| 2026-02-17 | Pennell Sandra |
Chief Financial Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Restricted Stock Units
|
28,250 |
| 2026-02-17 | MICHEL GERARD J |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Restricted Stock Units
|
97,500 |
| 2026-02-17 | MICHEL GERARD J |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
195,000 |
| 2026-02-17 | Muir Kevin |
GM INTERVENTIONAL ONCOLOGY |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Restricted Stock Units
|
28,250 |
| 2026-02-17 | Muir Kevin |
GM INTERVENTIONAL ONCOLOGY |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
56,500 |
| 2026-02-17 | Rook Martha S. |
CHIEF OPERATING OFFICER |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Restricted Stock Units
|
28,250 |
| 2026-02-17 | Hoffman David L. |
GEN'L COUNSEL, CCO & SECY |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
56,500 |
| 2026-02-17 | Vukovic Vojo |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
56,500 |
| 2026-02-17 | Hoffman David L. |
GEN'L COUNSEL, CCO & SECY |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. |
Restricted Stock Units
|
28,250 |
| 2025-11-21 | Sylvester John Richard |
Director |
Buy↑
|
Common Stock
|
4,386 |
| 2025-11-11 | MICHEL GERARD J |
Director, CHIEF EXECUTIVE OFFICER |
Buy↑
|
Common Stock
|
11,500 |
| 2025-06-12 | Vukovic Vojo |
CHIEF MEDICAL OFFICER |
Convert↓
Filing footnotes — Employee Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 12, 2024 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Employee Stock Option (Right to Buy)
|
42,000 |
| 2025-06-12 | Vukovic Vojo |
CHIEF MEDICAL OFFICER |
Convert↑
|
Common Stock
|
42,000 |
| 2025-05-15 | Martell Bridget A |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2025-05-15 | Sylvester John Richard |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2025-05-15 | Aharon Gil |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2025-05-15 | CZEREPAK ELIZABETH |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2025-05-15 | SALAMON STEVEN A J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 15, 2025 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service. |
Stock Option (right to buy)
|
22,500 |
| 2025-05-05 | Rosalind Advisors, Inc. |
Director |
Exercise↑
Filing footnotes — Common shares (Indirect)
Rosalind Opportunities Fund I L.P. exercised warrants to aquire 400,000 common shares. Rosalind Master Fund L.P. - 1,565,844, Rosalind Opportunities Fund I L.P. - 1,734,545, Steven Salamon - 82,197, Gilad Aharon - 30,882 Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common shares
(I)
|
400,000 |
| 2025-05-05 | Aharon Gil |
Director |
Exercise↑
Filing footnotes — Common shares (Indirect)
Rosalind Opportunities Fund I L.P. exercised warrants to aquire 400,000 common shares. Rosalind Master Fund L.P. - 1,565,844, Rosalind Opportunities Fund I L.P. - 1,734,545, Steven Salamon - 82,197, Gilad Aharon - 30,882 Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common shares
(I)
|
400,000 |
| 2025-05-05 | SALAMON STEVEN A J |
Director |
Exercise↑
Filing footnotes — Common shares (Indirect)
Rosalind Opportunities Fund I L.P. exercised warrants to aquire 400,000 common shares. Rosalind Master Fund L.P. - 1,565,844, Rosalind Opportunities Fund I L.P. - 1,734,545, Steven Salamon - 82,197, Gilad Aharon - 30,882 Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common shares
(I)
|
400,000 |
| 2025-02-07 | Rook Martha S. |
CHIEF OPERATING OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
113,000 |
| 2025-02-07 | Hoffman David L. |
GEN'L COUNSEL, CCO & SECY |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
113,000 |
| 2025-02-07 | Pennell Sandra |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
113,000 |
| 2025-02-07 | Muir Kevin |
GM INTERVENTIONAL ONCOLOGY |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
113,000 |
| 2025-02-07 | MICHEL GERARD J |
Director, CHIEF EXECUTIVE OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
390,000 |
| 2025-02-07 | Vukovic Vojo |
CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). |
Stock Option (Right to Buy)
|
113,000 |
| 2024-12-24 | Rosalind Advisors, Inc. |
Director |
Convert↑
Filing footnotes — Pre-funded Warrants (Indirect)
Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00. NA Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Pre-funded Warrants
(I)
|
603,954 |
| 2024-12-24 | Aharon Gil |
Director |
Other↑
Filing footnotes — Common shares (Indirect)
Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00. Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common shares
(I)
|
250,000 |
| 2024-12-24 | SALAMON STEVEN A J |
Director |
Convert↑
Filing footnotes — Pre-funded Warrants (Indirect)
Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00. NA Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Pre-funded Warrants
(I)
|
603,954 |
| 2024-12-24 | Rosalind Advisors, Inc. |
Director |
Other↑
Filing footnotes — Common shares (Indirect)
Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00. Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common shares
(I)
|
250,000 |
| 2024-12-24 | SALAMON STEVEN A J |
Director |
Other↑
Filing footnotes — Common shares (Indirect)
Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00. Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Common shares
(I)
|
250,000 |
| 2024-12-24 | Aharon Gil |
Director |
Convert↑
Filing footnotes — Pre-funded Warrants (Indirect)
Converted a total of 853,954 Series E/E-1 warrants to 603,954 Pre-funded Warrants at $9.99 and 250,000 common shares at $10.00. NA Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
Pre-funded Warrants
(I)
|
603,954 |